Horizon Therapeutics Doses First Patient in Alopecia Clinical Trial

Horizon Therapeutics plc (Nasdaq: HZNP) has dosed the first patient in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata.

Alopecia areata is a complex disease with a significant unmet medical need, where patients can experience patchy or total hair loss that can impact their quality of life.

Jodie Morrison, board member and acting chief executive officer, Q32 Bio, said, “Dosing of the first patient in the Phase 2 study in alopecia areata, in addition to our ongoing Phase 2 study in atopic dermatitis, demonstrate the breadth of potential applications of bempikibart and our deep commitment to transform the lives of patients with autoimmune and inflammatory diseases.”


Bempikibart is a fully human antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP. It represents a potential unique approach to correcting immune system dysregulation in alopecia and other diseases.

Horizon and Q32 Bio believe that bempikibart  has the potential to provide long-term, durable improvement in hair loss, including the potential for disease remittance.

Alopecia areata is a common, acute onset, autoimmune disorder that affects hair follicles and is characterized by transient, non-scarring hair loss.

About Horizon

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.

The Company’s most advanced program, bempikibart, is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function and is being developed in collaboration with Horizon Therapeutics for the treatment of autoimmune diseases, including Phase 2 trials in both atopic dermatitis and alopecia areata. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

Q32 Bio’s lead program for innate immunity, ADX-097, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio has recently completed a first-in-human, Phase 1, ascending dose (SAD/MAD) clinical study of ADX-097 in healthy volunteers. For more information, please visit www.Q32bio.com.

Share This Article


About the Author

Horizon Therapeutics Doses First Patient in Alopecia Clinical Trial

Catie Corcoran

Biotech Editor